Educational Resources

Response Assessment in RPTs for Prostate Cancer: Everyone’s A Winner

The 2024 Society of Nuclear Medicine & Molecular Imaging (SNMMI) annual meeting featured a session on prostate cancer, and a presentation by Professor Louise Emmett discussing response assessment in radiopharmaceutical therapies for prostate cancer.

For the presentation on UroToday click here.

Comparing PSMA Ligands for Prostate Cancer Imaging

Professor Michael Hofman (Prostate Cancer Theranostics Imaging and Centre of Excellence [ProsTIC], Peter MacCallum Cancer Centre) was recently interviewed on the similarities and differences among available PSMA ligands for PET-CT imaging and treatment in the US and elsewhere, along with clinical use decision-making and the latest research.

You can listen to the recording on UroToday here.

Brain FDG PET tutorials on-line

Item 61560 for PET for the diagnosis of Alzheimer’s Disease in patients where other diagnostic methods are equivocal was introduced on 1st November 2021.

Our international expert member on dementia imaging, Professor Christopher Rowe from Austin Health in Melbourne, championed this MSAC application, and he has now put together two 60 minute tutorials to update members’ knowledge and help them better understand the interpretation of FDG PET in Dementia.

These tutorials can be accessed through the Australian Dementia Network (ADNet), of which Chris is also the Director:

We thank Chris for providing this valuable resource for all nuclear medicine clinicians.

Continuing Professional Development (CPD) websites:

> The Australian Medical Association (AMA)

> The Royal Australasian College of Physicians (RACP) 

>The Royal Australian and New Zealand College of Radiologists (RANZCR) 

Cancer websites:

> https://engage.australiancancerplan.gov.au/acp

> https://www.canceraustralia.gov.au/cancer-types/neuroendocrine-tumours/statistics

> https://wiki.cancer.org.au/australia/COSA:NETs_guidelines

NeuroEndocrine:

> https://neuroendocrine.org.au/get-involved/net-national-action-plan/

> https://neuroendocrine.org.au/planetregistry/

> https://www.enets.org/

Prostate Cancer:

Online Resources for LuPSMA

Guidelines

• Advanced Prostate Cancer Consensus Guidelines 2019, 2021, 2022   https://www.apccc.org/publications-slides.html
• EANM Lutetium PSMA Procedure Guidelines https://pubmed.ncbi.nlm.nih.gov/31440799/
• E-PSMA standardized reporting guidelines v1.0  https://pubmed.ncbi.nlm.nih.gov/33604691/
• Cancer Council Prostate Cancer guidelines (2022 coming soon) https://www.cancer.org.au/health-professionals/clinical-practice-guidelines/prostate-cancer
• Prostate Cancer Working Group Criteria v3.0 (PSA endpoints, CT/bone scan) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872347/

Review papers

• Radiographics: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls   https://pubmed.ncbi.nlm.nih.gov/29320333/
• LuPSMA: practical nuances and intricacies   https://pubmed.ncbi.nlm.nih.gov/31595044/

Key primary research papers

• TheraP randomised study, Lancet 2021  https://pubmed.ncbi.nlm.nih.gov/33581798/
• ProPSMA randomised study, Lancet 2020  https://pubmed.ncbi.nlm.nih.gov/32209449/
• VISION Trial, NEJM 2021   https://pubmed.ncbi.nlm.nih.gov/34161051/
• LuPSMA, first phase 2 study Lancet Oncology 2018   https://pubmed.ncbi.nlm.nih.gov/29752180/
• LuPSMA, long-term follow-up JNM 2020   https://pubmed.ncbi.nlm.nih.gov/31732676/
• Whole body tumour dosimetry, JNM 2019   https://pubmed.ncbi.nlm.nih.gov/30291192/

Online resources

• Comparing PSMA Ligands for Prostate Cancer Imaging – Interview with Professor Michael Hofman FRACP FAANMS, UroToday, 31 May 2024
• ProsTIC Preceptorship    https://prosticpreceptorship2022.org
• GU Cast Podcast    https://www.gucast.org/
• ProsTIC    https://www.petermac.org/ProsTIC
• ProsTIC TV   https://www.youtube.com/ProsTICTV

Thyroid:

> https://tiro.expert/

> https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739132/  ATA guidelines

> https://www.cancer.org.au/assets/pdf/understanding-thyroid-cancer-booklet